TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2683543
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral blockade with bupivacaine 0.5% (15 ml followed by 5 ml/h)
Study: 2683543
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural blockade with bupivacaine 7 ml 0.5% + morphine 2 mg followed by 5 ml/h + 0.2 mg/h
Study: 29785889
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation at 0.5 g/kg feed
Study: 29785889
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation at 1.0 g/kg feed
Study: 29785889
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation at 2.0 g/kg feed
Study: 24119149
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU) administered orally every week for 8 weeks
Study: 24119149
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally every week for 8 weeks
Study: 22026529
Drug: Genuine auricular
Normalized name: Genuine First Aid - Auto First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genuine auricular therapy
Study: 22026529
Drug: Sham auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham auricular therapy (control)
Study: 22026529
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (genuine auricular therapy and sham)
Study: 19187286
Drug: Albiglutide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (0.25 + 1 mg, 3 + 6 mg, 16 + 24 mg, 48 + 60 mg, 80 + 104 mg)
Study: 16280089
Drug: NSAIDs and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs and/or SMT in addition to general practitioner advice and paracetamol
Study: 10326923
Drug: Gel cushion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel cushion (tilted position)
Study: 10326923
Drug: Gel cushion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel cushion (upright position)
Study: 8566580
Drug: Intracolonic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracolonic injection of glycerol
Study: 8566580
Drug: Intrarectal injection
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal injection of glycerol
Study: 8566580
Drug: Lidocaine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (administered prior to glycerol injection)
Study: 8566580
Drug: Paraffin oil
Normalized name: Paraffin Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin oil (control for glycerol injection)
Study: 8566580
Drug: Octreotide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide and granisetron (drugs acting on visceral afferent pathways)
Study: 8566580
Drug: Phloroglucinol (spasmolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol (spasmolytic drug)
Study: 7184471
Drug: Topical tuberculin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tuberculin jelly (14 patients)
Study: 17572422
Drug: Micronized 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17beta‐estradiol 1 mg plus dydrogesterone 10 mg sequential added (LD‐HT; group A)
Study: 17572422
Drug: Dydrogesterone 10
Normalized name: dydrogesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg from day 15 to 28 (group B)
Study: 8824737
Drug: Other Ayurvedic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Ayurvedic formulations
Study: 30686952
Drug: GC1107 (adult
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1107 (adult tetanus diphtheria vaccine)
Study: 30686952
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Td vaccine)
Study: 25608632
Drug: Flurbiprofen Axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen Axetil (FA) with fentanyl in postoperative controlled intravenous analgesia (PCIA)
Study: 23592107
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave + placebo infusion
Study: 19419845
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Pindolol
Study: 16684688
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (Ventoline Diskhaler) 200 microg three times a day
Study: 11736858
Drug: (+)-chlorpheniramine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-chlorpheniramine 6 mg
Study: 9246150
Drug: Single i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. dolasetron dose (0.6 mg/kg) before cisplatin
Study: 9246150
Drug: Multiple i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple i.v. dose regimen (0.6 mg/kg x 3) given before and after cisplatin
Study: 31160146
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day for four days)
Study: 19696637
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (prednisone) for 3 months
Study: 19696637
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (prednisone, cyclosporine, and mycophenolate)
Study: 8259034
Drug: Total therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapeutic paracentesis (TTP) plus i.v. albumin (5 g/l of fluid)
Study: 3519644
Drug: Bromocriptine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (1.25 mg twice daily, increased to 2.5 mg twice daily if no improvement)
Study: 28688525
Drug: FDG-guided dose-escalation
Normalized name: (18F)-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-guided dose-escalation (mean doses of 95Gy for tumour and 74Gy for lymph nodes)
Study: 28688525
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (66Gy/33F plans)
Study: 25714724
Drug: A standardized
Normalized name: Echinacea 400 MG Oral Capsule [ECHINACEA STANDARDIZED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized extract from Ageratina pichinchensis (5 %, cream formulation)
Study: 22836585
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg/week in addition to TPTD
Study: 22836585
Drug: Raloxifene (RAL)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RAL) 60 mg/d in addition to TPTD
Study: 22836585
Drug: TPTD monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPTD monotherapy (no additional medication)
Study: 16464979
Drug: Subacromial fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subacromial fentanyl 4 microg ml(‐1) (Group F)
Study: 16464979
Drug: i.v. fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fentanyl 4 microg ml(‐1) (Group C)
Study: 15142198
Drug: Asacol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol (800 mg)
Study: 15142198
Drug: Balsalazide (2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide (2250 mg)
Study: 9762783
Drug: formoterol dry
Normalized name: aclidinium / formoterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol dry powder 24 microg twice daily (08:00 and 20:00 h)
Study: 9762783
Drug: formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol 24 microg once daily (20:00 h)
Study: 28349504
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravitreal bevacizumab (IVB) injection
Study: 28349504
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1.25 mg IVB and 1 mg intravitreal triamcinolone (IVT)
Study: 28349504
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1.25 mg IVB and 1 mg IVT
Study: 21312288
Drug: Vehicle plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle plus 75 g of glucose
Study: 21312288
Drug: Vehicle plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle plus 75 mg of caffeine
Study: 21312288
Drug: Vehicle plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle plus 75 g of glucose and 75 mg of caffeine
Study: 21312288
Drug: Vehicle (water,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (water, 150 ml)
Study: 18221474
Drug: Simultaneous intramuscular
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous intramuscular influenza and pneumococcal heptavalent conjugate vaccinations (IV + PV)
Study: 16773418
Drug: Ayurvedic polyherbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic polyherbal preparation 'Shathavaryadi Yoga (NS001)'
Study: 12742282
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg/day, n = 15)
Study: 12742282
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day, n = 15)
Study: 12742282
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (Atorvastatin and Simvastatin)
Study: 8827017
Drug: Prechemotherapy G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prechemotherapy G‐CSF (administered subcutaneously twice per day for 5 days at a dose of 5 micrograms/kg)
Study: 8827017
Drug: Postchemotherapy G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postchemotherapy G‐CSF (administered subcutaneously once per day for 7 days at a dose of 5 micrograms/kg)
Study: 8827017
Drug: Prechemotherapy G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prechemotherapy G‐CSF
Study: 8827017
Drug: Postchemotherapy G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postchemotherapy G‐CSF
Study: 1462413
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g at bedtime
Study: 3892050
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin immunotherapy
Study: 3892050
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin immunotherapy with positive skin test conversion
Study: 3892050
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin immunotherapy with negative skin test
Study: 3892050
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin immunotherapy with previously positive skin test
Study: 3892050
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin immunotherapy in high-risk patients
Study: 30920684
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive processing therapy
Study: 30920684
Drug: Group present-centered
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group present-centered therapy
Study: 29081351
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) plus pill placebo
Study: 29081351
Drug: Sertraline (SERT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SERT) plus Enhanced Medication Management (EMM)
Study: 29081351
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PE/SERT)
Study: 23700945
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous omega-3 PUFAs (Omegaven 10%) infusion
Study: 23700945
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution infusion (control group)
Study: 12973173
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution (30% glucose in water with insulin 50 U/L, and KCl 40 mM/L) at 1.5 mL/kg/hr for 24 hrs
Study: 10696980
Drug: No interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No interferon therapy
Study: 23511293
Drug: Gabapentin (dosage:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (dosage: 300 mg TID, 600 mg TID, 800 mg TID, 1200 mg TID)
Study: 12426230
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg loading dose and 10 mg/hour until Day 3)
Study: 31405764
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily before surgery
Study: 29799960
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Study: 28057360
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47)
Study: 26174611
Drug: AZD0837 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 (oral direct thrombin inhibitor)
Study: 23428337
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 (2.5, 10, or 60 mg)
Study: 23428337
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 (30 mg)
Study: 21526919
Drug: Routine upfront
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine upfront abciximab administration (bolus followed by 12-hour infusion)
Study: 21526919
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (selective abciximab use during intervention)
Study: 21526919
Drug: Routine upfront
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine upfront abciximab administration
Study: 16243440
Drug: Intravenous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amifostine 300 mg/m2
Study: 12527537
Drug: Standard Cognitive-Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive-Behavior Therapy (CBT)
Study: 12527537
Drug: Enhanced Cognitive-Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Cognitive-Behavior Therapy (ECBT)
Study: 10638560
Drug: Pantoprazole (PANT)
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole (PANT) 40 mg
Study: 10638560
Drug: Ranitidine (RAN)
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine (RAN) 300 mg
Study: 27894358
Drug: Daily online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily online math training (control condition)
Study: 21422713
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU/d) and Vitamin C (500 mg/d) supplementation
Study: 10539870
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d Zithromax for 3 days then 600 mg/wk for 11 additional weeks
Study: 2317751
Drug: Simultaneous combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous combined technique therapy (SIM)
Study: 2317751
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined technique therapy (SEQ)
Study: 30526388
Drug: Acacia bark
Normalized name: ROBINIA PSEUDOACACIA BARK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia bark extract tablets
Study: 22622962
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (choline fenofibrate) 135 mg once daily
Study: 22622962
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus atorvastatin treatment
Study: 25369725
Drug: Cognitive-behavioral therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapies
Study: 9285657
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (amiodarone or sotalol)
Study: 3453292
Drug: Sotalol hydrochloride
Normalized name: Sotalol Hydrochloride
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sotalol hydrochloride 80 mg and hydrochlorothiazide 12.5 mg
Study: 30144304
Drug: Budesonide (BD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BD) 256 μg
Study: 30144304
Drug: Montelukast (MNT)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (MNT) 10 mg
Study: 30144304
Drug: Half-dose Budesonide
Normalized name: budesonide Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose Budesonide (hBD) 128 μg + Montelukast (MNT)
Study: 25526439
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 20 mg/kg/day for 2 years, then escalated to 30 mg/kg/day during extension study.
Study: 25526439
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 30 mg/kg/day, then decreased to 26 mg/kg/day (range 19.5-31.2).
Study: 25526439
Drug: Hydroxyurea therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy.
Study: 20527138
Drug: Onion extract
Normalized name: Onion Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion extract cream with Centella asiatica and hyaluronic acid applied twice daily for 12 weeks
Study: 20527138
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control) applied to the contralateral side
Study: 15228673
Drug: rhG‐CSF 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF 75 micro g per day s.c. for 5 ‐ 7 days, additional 3 ‐ 5 days according to leukopenia during radiotherapy
Study: 9113582
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine hydrochloride plus 0.1 mL subconjunctival lignocaine
Study: 3257288
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) 15 mg/kg/day
Study: 3257288
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) 15 mg/kg/day for 10 days
Study: 3257288
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) 15 mg/kg/day for 28 days
Study: 31777949
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg UPA per day for 5 days
Study: 28335012
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion for working memory improvement (4 sessions of 1 hour each)
Study: 28335012
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control group (no hypnotic suggestion)
Study: 28335012
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion for working memory improvement
Study: 21640056
Drug: Active conservative
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conservative treatment (pelvic floor muscle training - PFMT) delivered by a specialist continence physiotherapist or nurse
Study: 21640056
Drug: Active conservative
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conservative treatment (PFMT)
Study: 19537306
Drug: Margarine fortified
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine fortified with 200 microg folic acid/10 g portion (centre M)
Study: 16280233
Drug: Written text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written text with basic oral explanations (Control)
Study: 14756716
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg) + lower intensity counseling
Study: 14756716
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg) + higher intensity counseling
Study: 14756716
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg) + lower intensity counseling
Study: 14756716
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg) + higher intensity counseling
Study: 11425939
Drug: Deprenyl treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl treatment
Study: 3900847
Drug: Tocopherol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol treatment
Study: 11425939
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of deprenyl and tocopherol
Study: 9262882
Drug: 0.33 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.33 mg/kg PPA